Resumen de Study of in vivo mycobacterium tuberculosis transcripto in mouse model. Interaction of mtbvac with bladder cancer tumor cells
Nowadays, tuberculosis (TB) is the infectious disease that cause more deaths all around the world. It is caused by Mycobacterium tuberculosis (Mtb) and in the last years the increase in cases of TB have done the control of the disease a priority for the health systems of all countries.
In spite of the development of new drugs and vaccines against TB, the knowledge of the interactions between the bacteria and the host during the first steps of the infection is still scarce. We have developed a protocol that allows the study of the bacterial expression in murine models with different immune system capacities. The analysis of the obtained results shows a different expression in vivo comparing to in vitro conditions, and an ability of Mtb to modulate their antigenic production in function of the ability of the immune system of the host. Also, differences in expression between virulent strains of Mtb have been found.
On the other hand, the development of new vaccines and the fact that the Bacillus Calmette-Guérin (BCG), the current TB vaccine, is used for bladder cancer treatment makes us to study the possible use of new live attenuated TB vaccines for this type of cancer. Our results show that the TB vaccine candidate MTBVAC developed by our group has shown a better capacity of infection and direct cytotoxicity through the same internalization mechanism than BCG. The comparison of the efficacy of both vaccines in an orthotopic murine model of bladder cancer reveals a good prospective of MTBVAC to replace BCG as immunotherapy of this type of cancer.
